20:44 , Jan 3, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2018

New Therapeutic Targets and Biomarkers: December 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December. Therapeutic targets are defined as any protein, gene or other molecule...
16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting P4HA1 could help treat triple-negative breast cancer (TNBC). In tumor samples from TNBC patients, levels of P4HA1 protein were higher than in samples from estrogen...
08:00 , Nov 12, 2007 |  BC Week In Review  |  Clinical News

FG-2216: Phase I data

In a German Phase I trial in hemodialysis patients and healthy volunteers, single doses of FG-2216 increased median EPO levels to 240.6 from 7.8 mIU/mL in 6 patients with kidneys, and to 57.8 from 4.4...
08:00 , Nov 12, 2007 |  BC Week In Review  |  Clinical News

FG-4592: Preliminary Phase II data

Preliminary data from the first cohort of 29 patients in a placebo-controlled, dose-escalation Phase II trial in 8 evaluable patients showed that doses of up to 120 mg of FG-4592 were well tolerated. In 8...
07:00 , May 14, 2007 |  BC Week In Review  |  Clinical News

FG-2216: Phase II data

Astellas said a patient receiving FG-2216 died of fulminant hepatitis in a U.S. Phase II trial to treat anemia. The trial, which is being run by FibroGen, is ongoing and the case has been reported...